Abstract
Idiopathic Hypercalciuria (IH), a heterogenous disorder, is the most common cause of urolithiasis in children. IH patients present frequently with gross or microscopic hematuria, abdominal pain and a variety of urinary tract complaints (frequency-dysuria syndrome, enuresis, recurrent tract infection), with-noncalculus manifestation more prevalent than stone disease. Recently, osteopenia has been found in a high percentage of IH children even at the time of diagnosis. IH is characterized by urinary calcium excretion greater than 4mg/kg/day with normocalcemia in the absence of any other causes of hypercalciuria such as vitamin D intoxication, primary hyperparathyroidism, hyperthyroidism, immobilization, endogenous or exogenous glucocorticoid excess, distal renal tubular acidosis and furesemide medication. This complex metabolic disease is considered to be of genetic origin, as in some cases, it seems to be inherited in an autosomal dominant pattern. A variety of genes participating in the mechanisms of Ca homeostasis, have attracted the interest of researchers in order to elucidate the pathogenetic mechanism of the disease and thus determining the appropriate treatment for any distinct patient. However, no specific gene or polymorphisms are yet identified. Furthermore, studies on the pathophysiology of IH distinguish two prominent types of IH: the absorptive, characterized by increased intestinal Ca absorption, and the renal, characterized by decreased tubular Ca reabsorption. The distinction between renal and absorptive type could direct towards the better therapeutic protocol. Generally, the main goal of treatment applied on hypercalciuric children should be to alleviate and finally eliminate the symptoms of the disease, to prevent renal stone formation or recurrence and to permit the acquisition of the optimal bone mass. Initial management of those patients consists primarily of high fluid intake and dietary salt restriction. If the symptoms persist, thiazide diuretics prescription is ideal, especially for IH patients of renal type.
Keywords: Urolithiasis, hematuria, hyperparathyroidism, Osseous Resorption, CLCN5 mutations
Current Pediatric Reviews
Title: Idiopathic Hypercalciuria in Children
Volume: 2 Issue: 1
Author(s): Polyxeni Nicolaidou and Anna Papadopoulou
Affiliation:
Keywords: Urolithiasis, hematuria, hyperparathyroidism, Osseous Resorption, CLCN5 mutations
Abstract: Idiopathic Hypercalciuria (IH), a heterogenous disorder, is the most common cause of urolithiasis in children. IH patients present frequently with gross or microscopic hematuria, abdominal pain and a variety of urinary tract complaints (frequency-dysuria syndrome, enuresis, recurrent tract infection), with-noncalculus manifestation more prevalent than stone disease. Recently, osteopenia has been found in a high percentage of IH children even at the time of diagnosis. IH is characterized by urinary calcium excretion greater than 4mg/kg/day with normocalcemia in the absence of any other causes of hypercalciuria such as vitamin D intoxication, primary hyperparathyroidism, hyperthyroidism, immobilization, endogenous or exogenous glucocorticoid excess, distal renal tubular acidosis and furesemide medication. This complex metabolic disease is considered to be of genetic origin, as in some cases, it seems to be inherited in an autosomal dominant pattern. A variety of genes participating in the mechanisms of Ca homeostasis, have attracted the interest of researchers in order to elucidate the pathogenetic mechanism of the disease and thus determining the appropriate treatment for any distinct patient. However, no specific gene or polymorphisms are yet identified. Furthermore, studies on the pathophysiology of IH distinguish two prominent types of IH: the absorptive, characterized by increased intestinal Ca absorption, and the renal, characterized by decreased tubular Ca reabsorption. The distinction between renal and absorptive type could direct towards the better therapeutic protocol. Generally, the main goal of treatment applied on hypercalciuric children should be to alleviate and finally eliminate the symptoms of the disease, to prevent renal stone formation or recurrence and to permit the acquisition of the optimal bone mass. Initial management of those patients consists primarily of high fluid intake and dietary salt restriction. If the symptoms persist, thiazide diuretics prescription is ideal, especially for IH patients of renal type.
Export Options
About this article
Cite this article as:
Nicolaidou Polyxeni and Papadopoulou Anna, Idiopathic Hypercalciuria in Children, Current Pediatric Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339606775518287
DOI https://dx.doi.org/10.2174/157339606775518287 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polyglandular Autoimmune Syndromes
Current Immunology Reviews (Discontinued) Occurrence of Interleukin-2 (330 G/T) Promoter Polymorphism in ARV associated hepatotoxicity
Current Molecular Medicine Cannabinoid Receptors as Therapeutic Targets
Current Pharmaceutical Design New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Mini-Reviews in Medicinal Chemistry The Use of Vitamin D in Respiratory Diseases
Current Respiratory Medicine Reviews Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence
Current Pharmaceutical Design Emerging Therapeutic Approaches to COVID-19
Current Pharmaceutical Design Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Limitations of Current Antiretroviral Agents and Opportunities for Development
Current Pharmaceutical Design Neuron-to-microglia Crosstalk in Psychiatric Disorders
Current Neuropharmacology Structure and Function of Complement Activating Enzyme Complexes C1 and MBL-MASPs
Current Protein & Peptide Science Acute Toxicological and Histopathological Elucidation of <i>Rheum emodi</i> Rhizome Extract to Demonstrate Antidiabetic Activity in Alloxan-induced Diabetic Rats
Current Bioactive Compounds Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry Regulation of EMT by KLF4 in Gastrointestinal Cancer
Current Cancer Drug Targets Recent Developments in Group I Metabotropic Glutamate Receptor Allosteric Modulators for the Treatment of Psychiatric and Neurological Disorders (2014-May 2015)
Current Topics in Medicinal Chemistry Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design The Antioxidants and Pro-Antioxidants Network: An Overview
Current Pharmaceutical Design Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances
Current Cancer Therapy Reviews A Comprehensive Review on Perfusion Method Development for Bone Marrow Collection and Stem Cell Transplantation
Current Stem Cell Research & Therapy Structural Characterization of Recombinant Therapeutic Proteins by Circular Dichroism
Current Pharmaceutical Biotechnology